The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: A systematic review and meta-Analysis

Cardiology (Switzerland)

Volumn 131, Issue 2, 2015, Pages 86-96

  Zhang, Nan ^a   Lei, Jiayan ^a   Liu, Qing ^a   Huang, Wei ^a   Xiao, Hua ^a   Lei, Han ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Coronary artery bypass graft; Myocardial preservation; Myocardium; Trimetazidine

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; TRIMETAZIDINE; TROPONIN I; TROPONIN T; BIOLOGICAL MARKER; CARDIOTONIC AGENT; TROPONIN; VASODILATOR AGENT;

ARTICLE; CARDIAC PATIENT; CORONARY ARTERY BYPASS SURGERY; DRUG EFFICACY; ENZYME BLOOD LEVEL; HEART MUSCLE; HEART MUSCLE INJURY; HUMAN; META ANALYSIS; PRESERVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ADVERSE EFFECTS; CORONARY ARTERY BYPASS GRAFT; METABOLISM; MYOCARDIAL REPERFUSION INJURY; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROCEDURES;

BIOMARKERS; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; CREATINE KINASE, MB FORM; HUMANS; MYOCARDIAL REPERFUSION INJURY; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIMETAZIDINE; TROPONIN; VASODILATOR AGENTS;

EID: 84927914145     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000375289     Document Type: Article

References (37)

1. Varnauskas E: Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319: 332-337.
2. Hoffman JW Jr, et al: Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol 2004; 36: 391-411.
3. Weman SM, et al: Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting. Ann Thorac Surg 2000; 70: 807-812.
4. Moore GW, Hutchins GM: Coronary artery bypass grafts in 109 autopsied patients. Statistical analysis of graft and anastomosis patency and regional myocardial injury. JAMA 1981; 246: 1785-1789.
5. Klatte K, et al: Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol 2001; 38: 1070-1077.
6. Lopaschuk GD, et al: Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93:e33-e37.
7. Danchin N, et al: Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-Analysis. Cardiology 2011; 120: 59-72.
8. Hu B, et al: Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-Analysis of randomized, controlled trials. Clin Cardiol 2011; 34: 395-400.
9. Zhou X, Chen J: Is treatment with trimetazidine beneficial in patients with chronic heart failure PLoS One 2014; 9:e94660.
10. Zhang L, et al: Additional use of trimetazidine in patients with chronic heart failure: a metaanalysis. J Am Coll Cardiol 2012; 59: 913-922.
11. Liu Y, Li L, Su Q, Liu T, Tang Z: Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function. Cardiology 2015; 130: 130-136.
12. Kemp M, et al: Biochemical markers of myocardial injury. Br J Anaesth 2004; 93: 63-73.
13. Liberati A, et al: The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1-e34.
14. Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions version 5.1. 0 (updated March 2011). The Cochrane Collaboration 2011. www.cochranehandbook. org.
15. Moher D, et al: Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
16. Cohen J: Statistical Power Analysis for the Behavioral Sciences. New York, Routledge Academic, 2013.
17. Higgins J, Thompson SG: Quantifying heterogeneity in a meta-Analysis. Stat Med 2002; 21: 1539-1558.
18. Higgins J, et al: Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-560.
19. Sher-i-Murtaza M, Zubair M, Jalal A: Is there any benefit of preoperative oral trimetazidine in coronary artery bypass graft J Pak Med Assoc 2012; 62: 1271-1276.
20. Tünerir B, et al: Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68: 2173-2176.
21. Vedrinne J-M, et al: Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 1996; 82: 712-718.
22. Iskesen I, et al: Trimetazidine may protect the myocardium during cardiac surgery. The Heart Surgery Forum 2009; 12: 175-179.
23. Xu P, Wen B, Jiao Z, Liu C, Zhao W: The cardioprotective effects of trimetazidine during off-pump coronary artery bypass grafting. Henan Med Res 2014; 23: 29-31.
24. Wang H, Hu D, Jia S: The cardioprotective efficacy of TMZ during coronary artery bypass graft surgery. Chin J Med Guide 2003; 5: 017.
25. Chrusciel P, Rysz J, Banach M: Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs 2014; 74: 971-980.
26. Marzilli M, Klein WW: Efficacy and tolerability of trimetazidine in stable angina: a metaanalysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003; 14: 171-179.
27. Ciapponi A, Pizarro R, Harrison J: Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4:CD003614.
28. Belsey J, et al: Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and metaanalysis. Eur J Prev Cardiol 2014, Epub ahead of print.
29. Gao D, et al: Trimetazidine: a meta-Analysis of randomised controlled trials in heart failure. Heart 2011; 97: 278-286.
30. Grande P, et al: Estimation of acute myocardial infarct size in man by serum CK-MB measurements. Circulation 1982; 65: 756-764.
31. Babuin L, Jaffe AS: Troponin: the biomarker of choice for the detection of cardiac injury. Can Med Assoc J 2005; 173: 1191-1202.
32. Adabag AS, et al: Prognostic significance of elevated cardiac troponin I after heart surgery. Ann Thorac Surg 2007; 83: 1744-1750.
33. Paparella D, et al: Myocardial injury after offpump coronary artery bypass grafting operation. Eur J Cardiothorac Surg 2007; 32: 481-487.
34. Januzzi JL, et al: A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol 2002; 39: 1518-1523.
35. Males RG, Stephenson J, Harris P: Cardiac markers and point-of-care testing: a perfect fit. Crit Care Nurs Q 2001; 24: 54-61.
36. Petäjä L, et al: Biochemical injury markers and mortality after coronary artery bypass grafting: a systematic review. Ann Thorac Surg 2009; 87: 1981-1992.
37. Lopatin I, Dronova E: Clinical-pharmacoeconomic aspects of trimetazidine modified release use in patients with ischemic heart disease undergoing coronary artery bypass grafting (in Russian). Kardiologiia 2008; 49: 15-21.